Lilly’s Ixekizumab Results More Than Skin Deep In Psoriasis Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma presented positive Phase III data for the psoriasis drug when compared with placebo and the current standard of care, Amgen’s Enbrel. Lilly plans to submit the IL-17 inhibitor for approval by mid-2015.